Head and Neck Cancer
Also known as: Skull, Cranium, Head, Cranial, Larynx
Methodology & AI Transparency ⓘ
Head and Neck Cancer Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is head and neck cancer? Head and neck cancer is the name for cancers that develop in the mouth , nose and sinuses , salivary glands , and throat and voice box (larynx).
- 2 Real-world patient consensus: Mapped to Cancer, Oncology & Supportive Care under ICD-10-CM C76.0 for Head and Neck Cancer clinical workups.
- 3 Typical cash cost range: Differential triage of Head and Neck Cancer (C76.0) utilizes targeted/immunotherapy [Head and Neck Cancer C76.0].
- 4 Top reported side effects / signs: Key Cancer & Oncology biomarkers for Head and Neck Cancer (C76.0): Pathology / Molecular in Head and Neck Cancer (C76.0: Genomic Staging) & Complete Blood Count in Head and Neck Cancer (C76.0: (ANC, Hemoglobin, Platelets)) (Safe hematologic reserve (C76.0)).
Ask our AI Specialists anything about Head and Neck Cancer
What Is Head and Neck Cancer?
What is head and neck cancer? Head and neck cancer is the name for cancers that develop in the mouth , nose and sinuses , salivary glands , and throat and voice box (larynx). Most head and neck cancers are squamous cell cancers . They begin in the moist tissues that line the head and neck. The cancer cells may spread into deeper tissue as the cancer grows. There are other cancers that develop in the head and neck, such as brain cancer , eye cancer , and esophageal cancer . But they are usually not considered to be head and neck cancers, because those types of cancer and their treatments are different.
Pathophysiology, Underlying Causes & Clinical Presentation
Head and Neck Cancer (C76.0) alters cancer & oncology homeostasis through immune-checkpoint evasion [Head and Neck Cancer C76.0]; Cross-referenced with NIH MeSH (Head and Neck Neoplasms), clinical remission targets Complete Blood Count in Head and Neck Cancer (C76.0: (ANC, Hemoglobin, Platelets)) within Safe hematologic reserve (C76.0).
Common Symptoms & Clinical Signs
- • Use tobacco or drink lots of alcohol. Your risk of developing head and neck cancer is even higher if you do both
- • Have a history of head or neck cancer
- • Presentation of Head and Neck Cancer (C76.0): unintended weight loss [Head and Neck Cancer C76.0]
- • Secondary Head and Neck Cancer clinical sign: unexplained bleeding, chronic in Head and Neck Cancer (C76.0: hoarseness/cough, or progressive)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Head and Neck Cancer Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C76.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Pathology / Molecular in Head and Neck Cancer (C76.0: Genomic Staging) | Guideline-concordant surveillance (C76.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Head and Neck Cancer (C76.0: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C76.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Head and Neck Cancer (C76.0: Organ Function Panel) | Preserved renal/hepatic clearance (C76.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Head and Neck Cancer
Treatment selection for Head and Neck Cancer depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Head and Neck Cancer)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Eptinezumab improved patient-reported outcomes in patients with migraine and: What a 1,072-Participant Study Found This subgroup analysis in patients with CM/MOH at baseline suggests that eptinezumab treatment is associated with early, sustained, and clinically meaningful improvements in patient-reported outcomes. Headache • 2023-02-15 • Phase III Randomized Trial | N = 1,072 | 96/100 | PMID 36633219 ↗ |
| New Insights on Doravirine Resistance Patterns Identified Through Week 192 in the DRIVE-FORWARD: What a 502-Participant Study Found In DRIVE-FORWARD and DRIVE-AHEAD, the development of resistance to doravirine was uncommon (genotypic 1.3%; phenotypic 1.0%) and occurred mainly during the first 48 weeks of treatment. Journal of acquired immune deficiency syndromes (1999) • 2026-03-01 • Phase III Randomized Trial | N = 502 | 93/100 | PMID 41129125 ↗ |
| New Insights on Skin-applied Betamethasone Valerate As a Prophylactic Agent to Prevent Acute: What a 2,018,150-Participant Study Found Although prophylactic use of betamethasone significantly reduced the composite outcome of the proportion of patients developing grade 2 and grade 3 radiation dermatitis, it did not reduce the proportion of patients developing... International journal of radiation oncology, biology, physics • 2021-01-01 • Phase III Randomized Trial | N = 2,018,150 | 90/100 | PMID 32853709 ↗ |
| Can This Approach Help? Inside the Latest Research on Brief Report: Resolution of Neuropsychiatric side effects After Switching to a In both trial extensions, NPAEs persisted in 3%-4% of participants 96 weeks after switching to a DOR-based regimen, possibly representing the background rate for these events. Journal of acquired immune deficiency syndromes (1999) • 2025-05-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39748155 ↗ |
| Can This Approach Help? Inside the Latest Research on Preventive effect of the combination of atorvastatin and nortriptyline in In patients with migraine, prophylaxis with atorvastatin significantly improved the frequency of headache and QOL over 24 weeks compared with placebo with no effect on the intensity of headache. Neurological research • 2022-04-15 • Randomized Controlled Trial | N = 68 | 88/100 | PMID 35037597 ↗ |
Head and Neck Cancer Patient Community & “People Like Me” Threads
Filter Head and Neck Cancer community threads and patient logs by age, biological sex, dosage, and treatment duration.